单剂BNT162b2 mRNA疫苗在慢性髓性白血病患者中诱导中和抗体及多功能T细胞反应
该研究评估了16例接受酪氨酸激酶抑制剂(TKI)治疗的慢性髓性白血病(CML)患者接种第一剂BNT162b2疫苗后的体液和细胞免疫应答。数据表明单剂疫苗在多数CML患者中具有免疫原性。
要点
- 80%可评估患者出现多功能T细胞反应。
核心结论
- 单剂BNT162b2疫苗在多数接受TKI治疗的CML患者中可诱导中和抗体和多功能T细胞反应。
研究设计与样本
- 研究纳入16例接受TKI治疗的慢性髓性白血病患者,评估第一剂BNT162b2疫苗接种前后的血清转化和细胞免疫反应。
临床怎么用
- 对于接受TKI治疗的CML患者,单剂BNT162b2疫苗即可激发体液和细胞免疫应答,支持该人群接种疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID50 ) >50], including medium (ID50 of 200-500) or high (ID50 of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response nine of 15, polyfunctional CD8+ T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.
引用
- Harrington P, Doores KJ, Radia D, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021. PMID: 34085278. doi:10.1111/bjh.17568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。